TMTimothy J. Miles

Timothy J. Miles

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Timothy J. Miles has a total of 233 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Target product profile and discovery and development path for novel cryptococcal disease treatments

    by David B. Meya, Manu De Rycker, Ian H. Gilbert, William Hope, Justine Jelagat Odionyi, Michael Keegan, Angela Loyse, Pablo Moral-Lopez, Peter R. Williamson, Lionel K. Tan, et al.


  • Open Access

    Short-course combination treatment for experimental chronic Chagas disease

    by Silvia González, Richard J. Wall, John Thomas, Stephanie Braillard, Gino Brunori, Isabel Camino Díaz, Juan Cantizani, Sandra Carvalho, Pablo Castañeda Casado, Eric Chatelain, et al.

    Chagas disease, caused by the protozoan parasite Trypanosoma cruzi , affects millions of people in the Americas and across the world, leading to considerable morbidity and mortality. Current treatment options, benznidazole (BNZ) and nifurtimox, offer limited efficacy and often lead to adverse side effects because of long treatment durations. Better treatment options are therefore urgently required. Here, we describe a pyrrolopyrimidine series, identified through phenotypic screening, that offers an opportunity to improve on current treatments. In vitro cell-based washout assays demonstrate that compounds in the series are incapable of killing all parasites; however, combining these pyrrolopyrimidines with a subefficacious dose of BNZ can clear all parasites in vitro after 5 days. These findings were replicated in a clinically predictive in vivo model of chronic Chagas disease, where 5 days of treatment with the combination was sufficient to prevent parasite relapse. Comprehensive mechanism of action studies, supported by ligand-structure modeling, show that compounds from this pyrrolopyrimidine series inhibit the Q i active site of T. cruzi cytochrome b, part of the cytochrome bc 1 complex of the electron transport chain. Knowledge of the molecular target enabled a cascade of assays to be assembled to evaluate selectivity over the human cytochrome b homolog. As a result, a highly selective and efficacious lead compound was identified. The combination of our lead compound with BNZ rapidly clears T. cruzi parasites, both in vitro and in vivo, and shows great potential to overcome key issues associated with currently available treatments.


  • Open Access

    Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors

    by Michael G. Thomas, Kate McGonagle, Paul Rowland, David A. Robinson, Peter G. Dodd, Isabel Camino-Díaz, Lorna Campbell, Juan Cantizani, Pablo Castañeda, Daniel Conn, et al.

    There is an urgent need for new treatments for Chagas disease, a parasitic infection which mostly impacts South and Central America. We previously reported on the discovery of GSK3494245/DDD01305143, a preclinical candidate for visceral leishmaniasis which acted through inhibition of the Leishmania proteasome. A related analogue, active against Trypanosoma cruzi, showed suboptimal efficacy in an animal model of Chagas disease, so alternative proteasome inhibitors were investigated. Screening a library of phenotypically active analogues against the T. cruzi proteasome identified an active, selective pyridazinone, the development of which is described herein. We obtained a cryo-EM co-structure of proteasome and a key inhibitor and used this to drive optimization of the compounds. Alongside this, optimization of the absorption, distribution, metabolism, and excretion (ADME) properties afforded a suitable compound for mouse efficacy studies. The outcome of these studies is discussed, alongside future plans to further understand the series and its potential to deliver a new treatment for Chagas disease.


  • Open Access

    Author Correction: Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

    by Susan Wyllie, Michael Thomas, Stephen Patterson, Sabrinia Crouch, Manu De Rycker, Rhiannon Lowe, Stephanie Gresham, Michael D. Urbaniak, Thomas D. Otto, Laste Stojanovski, et al.

  • Open Access

    Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

    by Michael Thomas, Stephen Brand, Manu De Rycker, Fabio Zuccotto, Iva Lukac, Peter G. Dodd, Eun-Jung Ko, Sujatha Manthri, Kate McGonagle, Maria Osuna-Cabello, et al.

    There is an urgent need for new treatments for visceral leishmaniasis (VL), a parasitic infection which impacts heavily large areas of East Africa, Asia, and South America. We previously reported on the discovery of GSK3494245/DDD01305143 (1) as a preclinical candidate for VL and, herein, we report on the medicinal chemistry program that led to its identification. A hit from a phenotypic screen was optimized to give a compound with in vivo efficacy, which was hampered by poor solubility and genotoxicity. The work on the original scaffold failed to lead to developable compounds, so an extensive scaffold-hopping exercise involving medicinal chemistry design, in silico profiling, and subsequent synthesis was utilized, leading to the preclinical candidate. The compound was shown to act via proteasome inhibition, and we report on the modeling of different scaffolds into a cryo-EM structure and the impact this has on our understanding of the series’ structure–activity relationships.


  • Open Access

    Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis

    by Michael G. Thomas, Manu De Rycker, Myriam Ajakane, Sabrinia D. Crouch, Lorna Campbell, Alain Daugan, Gloria Fra, César Guerrero, Claire J. Mackenzie, Lorna MacLean, et al.

    Visceral leishmaniasis (VL) affects millions of people across the world, largely in developing nations. It is fatal if left untreated and the current treatments are inadequate. As such, there is an urgent need for new, improved medicines. In this paper, we describe the identification of a 6-amino-N-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine scaffold and its optimization to give compounds which showed efficacy when orally dosed in a mouse model of VL.


  • Open Access

    Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity

    by Michael G. Thomas, Manu De Rycker, Richard J. Wall, Daniel Spinks, Ola Epemolu, Sujatha Manthri, Suzanne Norval, Maria Osuna-Cabello, Stephen Patterson, Jennifer Riley, et al.

    Visceral leishmaniasis (VL) is a parasitic infection that results in approximately 26,000 – 65,000 deaths annually. The available treatments are hampered by issues such as toxicity, variable efficacy and unsuitable dosing options. The need for new treatments is urgent and led to a collaboration between the Drugs for Neglected Diseases initiative (DNDi), GlaxoSmithKline (GSK) and the University of Dundee. An 8-hydroxynaphthyridine was identified as a start point and an early compound demonstrated weak efficacy in a mouse model of VL but was hampered by glucuronidation. Efforts to address this led to the development of compounds with improved in vitro profiles, but these were poorly tolerated in vivo. Investigation of the mode of action (MoA) demonstrated that activity was driven by sequestration of divalent metal cations, a mechanism which was likely to drive the poor tolerability. This highlights the importance of investigating MoA and pharmacokinetics at an early stage for phenotypically active series.


  • Open Access

    The Qi Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani

    by Richard J. Wall, Sandra Carvalho, Rachel Milne, Juan A. Bueren-Calabuig, Sonia Moniz, Juan Cantizani-Perez, Lorna MacLean, Albane Kessler, Ignacio Cotillo, Lalitha Sastry, et al.

    Available treatments for Chagas’ disease and visceral leishmaniasis are inadequate and there is a pressing need for new therapeutics. Drug discovery efforts for both diseases principally rely upon phenotypic screening. However, the optimisation of phenotypically-active compounds is hindered by a lack of information regarding their molecular target(s). To combat this issue we initiate target deconvolution studies at an early stage. Here, we describe comprehensive genetic and biochemical studies to determine the targets of three unrelated phenotypically-active compounds. All three structurally-diverse compounds target the Qi active-site of cytochrome b, part of the cytochrome bc1 complex of the electron transport chain. Our studies go on to identify the Qi site as a promiscuous drug target in Leishmania donovani and Trypanosoma cruzi with a propensity to rapidly mutate. Strategies to rapidly identify compounds acting via this mechanism are discussed to ensure drug discovery portfolios are not overwhelmed with inhibitors of a single target.


  • Open Access

    Setting Our Sights on Infectious Diseases

    by Manu De Rycker, David Horn, Bree Aldridge, Richard K. Amewu, Clifton E. Barry, Frederick S. Buckner, Sarah Cook, Michael A. J. Ferguson, Nathalie Gobeau, Jennifer Herrmann, et al.

    In May 2019, the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering new medicines for infectious diseases and a particular focus on diseases affecting Low and Middle Income Countries. There is an urgent need for new drugs to treat most infectious diseases. We were keen to see if there were lessons that we could learn across different disease areas and between the preclinical and clinical phases with the aim of exploring how we can improve and speed up the drug discovery, translational, and clinical development processes. We started with an introductory session on the current situation and then worked backward from clinical development to combination therapy, pharmacokinetic/pharmacodynamic (PK/PD) studies, drug discovery pathways, and new starting points and targets. This Viewpoint aims to capture some of the learnings.


  • Open Access

    Optimisation of a key cross-coupling reaction towards the synthesis of a promising antileishmanial compound

    by Raul F. Velasco, César Guerrero, Gloria Fra, Alejandra Moure, Juan Miguel-Siles, Maria Teresa Quesada-Campos, Jose Ramon Ruiz-Gomez, Ian H. Gilbert, Michael G. Thomas, Timothy J. Miles